Integrative oncogenomic approaches for accelerated cancer-gene discovery

Current Opinion in Oncology

Volumn 20, Issue 1, 2008, Pages 72-76

  Zender, Lars ^a   Lowe, Scott W ^a,b  

^a Cold Spring Harbor Laboratory ^*  (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Array comparative genomic hybridization; Cancer mouse models; Comparative oncogenomics

Indexed keywords

ATM PROTEIN; PROTEIN KINASE B; RETROVIRUS VECTOR;

COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODEL; GENETIC ANALYSIS; HUMAN; MICROARRAY ANALYSIS; MOSAICISM; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; REVIEW; TUMOR GENE;

ANIMALS; GENOME, HUMAN; GENOMICS; HUMANS; MICE; ONCOGENES;

EID: 36549054355     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f31d5d     Document Type: Review

References (24)

1. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400:468-472.
2. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207.
3. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-660.
4. Verna L, Whysner J, Williams GM. 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol Ther 1996; 71:83-105.
5. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71:57-81.
6. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431:1112-1117.
7. Wang R, Ferrell LD, Faouzi S, et al. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 2001; 153:1023-1034.
8. Harada N, Oshima H, Katoh M, et al. Hepatocarcinogenesis in mice with betacatenin and Ha-ras gene mutations. Cancer Res 2004; 64:48-54.
9. Sandgren EP, Quaife CJ, Pinkert CA, et al. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 1989; 4:715-724.
10. Murakami H, Sanderson ND, Nagy P, et al. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 1993; 53:1719-1723.
11. Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001; 61:5389-5395.
12. Manickan E, Satoi J, Wang TC, Liang TJ. Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J Biol Chem 2001; 276:13989-13994.
13. Jhappan C, Stahle C, Harkins RN, et al. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990; 61:1137-1146.
14. Schmitt CA, Fridman JS, Yang M, et al. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1:289-298.
15. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-346.
16. Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005; 436: 807-811.
17. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92:3780-3792.
18. Zender L, Xue W, Cordon-Cardo C, et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol 2005; 70:251-261.
19. ··]) demonstrating the power of integrative oncogenomic approaches. In this study Yap and cIAP1 were identified and validated as oncogenes in liver cancer by cross-species oncogenomic comparison. Furthermore these genes could be identified as potential therapeutic targets.
20. Lucito R, Healy J, Alexander J, et al. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res 2003; 13:2291-2305.
21. ··]) demonstrating the power of integrative oncogenomic approaches. In this study cross-species oncogenomic comparison identified NEDD9 as a metastasis gene in melanoma.
22. Maser RS, Choudhury B, Campbell PJ, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447:966-971. This study illustrates how the introduction of mutations in DNA damage checkpoints can increase the rate of genomic alterations in genetically defined mouse tumors. The generation of humanized mouse tumors with increased frequencies of focal genomic deletions should facilitate cross-species oncogenomic comparison for the discovery of new tumor-suppressor genes.
23. Elledge SJ, Hannon GJ. An open letter to cancer researchers. Science 2005; 310:439-441.
24. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.